# Difference Between Epigenetics and Mutation: Key Concepts

## Introduction to Epigenetics and Mutation

[The central dogma of molecular biology](/blog/news/the-central-dogma-of-molecular-biology)—DNA to RNA to protein—describes the flow of genetic information, but it does not fully explain how the same genome can produce hundreds of distinct cell types, respond to environmental cues, or give rise to disease. Two distinct mechanisms account for much of this complexity: epigenetic modifications and mutations. Although both alter gene function, they operate at fundamentally different levels of biology.

A **mutation** is a permanent change in the nucleotide sequence of DNA. This change can be as small as a single [base pair substitution](/knowledge/molecular-biology/base-pair-substitution) or as large as a chromosomal rearrangement involving millions of base pairs. Because the DNA sequence itself is altered, mutations are typically irreversible and are faithfully copied during DNA replication. They alter the genetic blueprint directly.

An **[epigenetic modification](/knowledge/molecular-biology/epigenetic-modification)**, in contrast, is a reversible chemical change to DNA or to the proteins that package DNA, which affects gene expression without changing the underlying nucleotide sequence. The term "epigenetics" literally means "above" or "on top of" genetics. Epigenetic marks—such as methyl groups attached to cytosine bases or acetyl groups attached to histone proteins—can turn genes on or off, and they can be added or removed in response to developmental signals or environmental conditions.

The fundamental difference between epigenetics and mutation is therefore one of permanence and molecular substrate. Mutations change the sequence of DNA; epigenetic changes alter how that sequence is read. A mutation is like a typographical error in a book that permanently changes the text. An [epigenetic modification](/knowledge/molecular-biology/epigenetic-modification) is like a bookmark or a highlighted passage—it draws attention to certain content but does not alter the words themselves, and it can be removed at any time.

This distinction has profound implications for inheritance, disease, and evolution. Understanding it requires a closer look at the molecular mechanisms underlying each process, their effects on gene expression, and the methods used to study them. For a broader comparison of how these concepts relate to the genome as a whole, see the [Difference Between Genomics and Epigenetics](/knowledge/molecular-biology/difference-between-genomics-and-epigenetics).

## Molecular Mechanisms: Epigenetic Modifications vs. DNA Sequence Changes

### DNA Methylation and Histone Modifications

Epigenetic regulation operates through three principal mechanisms: DNA methylation, histone modification, and chromatin remodeling. Each involves chemical changes to the molecular components of chromatin—the complex of DNA and proteins that constitutes chromosomes.

**DNA methylation** is the covalent addition of a methyl group (–CH₃) to the fifth carbon of a cytosine residue, typically within a CpG dinucleotide (a cytosine followed by a guanine). This reaction is catalyzed by a family of enzymes called **DNA methyltransferases (DNMTs)** . DNMT3A and DNMT3B establish new methylation patterns during development (de novo methylation), while DNMT1 maintains existing patterns during DNA replication by recognizing hemimethylated CpG sites and methylating the newly synthesized strand. Methylation at promoter regions generally represses transcription by recruiting methyl-CpG-binding domain proteins, such as MeCP2, which in turn recruit histone deacetylases and other repressive complexes. Approximately 70–80% of CpG dinucleotides in the human genome are methylated, but CpG islands—regions of high CpG density often found in promoters—are usually unmethylated in active genes.

**Histone modifications** are post-translational modifications to the N-terminal tails of histone proteins, which protrude from the nucleosome core. Histone acetyltransferases (HATs) add acetyl groups to lysine residues, neutralizing the positive charge of the histone tail and weakening its interaction with negatively charged DNA. This opens the chromatin structure, allowing transcription factors access to the DNA. Histone deacetylases (HDACs) reverse this process. Methylation of histone lysine residues is more complex: trimethylation of histone H3 at lysine 4 (H3K4me3) is associated with active promoters, while trimethylation at lysine 27 (H3K27me3) is associated with gene silencing. These marks are written by histone methyltransferases and erased by demethylases such as LSD1 and the JmjC-domain family.

**Chromatin remodeling** involves ATP-dependent complexes, such as SWI/SNF, that physically reposition or evict nucleosomes, changing the accessibility of DNA to the transcriptional machinery. These complexes do not covalently modify DNA or histones; instead, they use the energy of ATP hydrolysis to slide histone octamers along the DNA or to exchange histone variants.

All three mechanisms are dynamic. Enzymes that add marks are balanced by enzymes that remove them, allowing cells to respond rapidly to signals. For example, the promoter of the *BDNF* gene in neurons can switch between methylated and unmethylated states within hours in response to neuronal activity.

### Types of Mutations

Mutations are alterations in the DNA sequence itself. They arise from errors during DNA replication, from damage caused by radiation or chemicals, or from the activity of mobile genetic elements. Mutations are classified by their scale and their effect on the genetic code.

**Point mutations** are changes to a single nucleotide. A **transition** replaces a purine with another purine (A↔G) or a pyrimidine with another pyrimidine (C↔T); a **transversion** replaces a purine with a pyrimidine or vice versa. Within a coding sequence, a point mutation can be:

- **Silent**: The codon change does not alter the amino acid due to the degeneracy of the genetic code. For example, a change from GAA to GAG both encode glutamate.
- **Missense**: The codon change results in a different amino acid. The classic example is the sickle cell mutation in the *HBB* gene, where a single A→T transversion changes codon 6 from GAG (glutamate) to GTG (valine).
- **Nonsense**: The codon change creates a premature stop codon, truncating the protein. For example, a C→T transition in the *CFTR* gene at codon 542 changes CGA (arginine) to TGA (stop), causing cystic fibrosis.

**Insertions and deletions** (indels) add or remove nucleotides. When the number of inserted or deleted nucleotides is not a multiple of three, the reading frame shifts, producing a **frameshift mutation** that alters every downstream amino acid and typically creates a premature stop codon. A well-known example is the ΔF508 mutation in *CFTR*, a three-nucleotide deletion that removes phenylalanine at position 508.

**Chromosomal mutations** affect large segments of DNA. **Deletions** remove a chromosomal region; **duplications** copy a region; **inversions** flip a segment end-to-end; **translocations** move a segment to a non-homologous chromosome. The Philadelphia chromosome, resulting from a translocation between chromosomes 9 and 22, fuses the *BCR* and *ABL1* genes and drives chronic myeloid leukemia.

Mutations can also be classified by their origin. **Somatic mutations** occur in non-germline cells and are not passed to offspring. **Germline mutations** occur in sperm or egg cells and are inherited by all cells of the resulting organism. The distinction between epigenetic changes and mutations is sometimes blurred by the fact that both can be inherited, but the mechanisms of inheritance differ fundamentally, as discussed in the section on heritability below.

## Effects on Gene Expression and Phenotype

### Epigenetic Regulation of Gene Expression

Epigenetic modifications control gene expression in a graded, reversible, and context-dependent manner. They do not change the information encoded in the DNA; rather, they determine whether that information is accessible to the transcriptional machinery.

The most direct effect of DNA methylation is transcriptional repression. When a promoter is methylated, transcription factors cannot bind, and methyl-CpG-binding proteins recruit co-repressor complexes that compact chromatin. This is how **genomic imprinting** works: the *IGF2* gene is expressed only from the paternal allele because the maternal allele is silenced by methylation at an imprinting control region. Similarly, **X-chromosome inactivation** in female mammals is initiated by the long non-coding RNA *XIST*, which recruits chromatin-modifying enzymes that deposit H3K27me3 and DNA methylation across the entire inactive X chromosome.

Histone modifications create a "histone code" that is read by effector proteins. Acetylation of histone H3 at lysine 9 (H3K9ac) and H3K14ac is associated with active promoters and enhancers. The bromodomain-containing protein BRD4 reads these acetylation marks and recruits the transcriptional elongation factor P-TEFb, which phosphorylates RNA polymerase II to promote productive transcription. In contrast, H3K9me3 and H3K27me3 recruit heterochromatin protein 1 (HP1) and Polycomb repressive complexes, respectively, establishing silenced chromatin domains.

Epigenetic regulation is essential for cellular differentiation. All cells in an organism share the same genome, but they express different sets of genes because they carry different epigenetic marks. The *Pax6* gene, for example, is unmethylated and active in the developing eye but methylated and silenced in other tissues. These patterns are established during development and maintained through cell division by DNMT1, which copies methylation marks from the parental to the daughter strand.

### Consequences of Mutations

Mutations alter gene expression or protein function in ways that are often binary: a gene is either functional or not, a protein either binds its target or does not. The phenotypic consequences depend on the type of mutation and its location.

**Loss-of-function mutations** reduce or eliminate the activity of a gene product. These are typically recessive, because one functional copy of the gene is sufficient to maintain the phenotype. For example, mutations in the *BRCA1* gene that truncate the protein abolish its role in DNA repair, predisposing carriers to breast and ovarian cancer. **Gain-of-function mutations** increase the activity of a gene product or confer a new function. These are typically dominant. The *RAS* oncogene, for instance, acquires constitutive activity through point mutations at codons 12, 13, or 61, locking the protein in its active GTP-bound state and driving uncontrolled cell proliferation.

Mutations in regulatory regions can alter gene expression without changing the protein sequence. A mutation in the promoter of the *β-globin* gene can reduce its transcription, causing β-thalassemia. Mutations in enhancers can change the timing or tissue specificity of gene expression. For a detailed discussion of how regulatory elements control transcription, see the [Difference Between Enhancer and Promoter](/knowledge/molecular-biology/difference-between-enhancer-and-promoter).

The key distinction is that mutations change the information content of the genome, while epigenetic changes alter its interpretation. A mutation in the coding region of *TP53* can produce a non-functional protein that fails to suppress tumors. An epigenetic change that methylates the *TP53* promoter can silence the gene entirely, producing the same loss of function without any change to the DNA sequence. Both mechanisms contribute to cancer, but they require different therapeutic approaches.

## Heritability and Stability Across Generations

### Transgenerational [Epigenetic Inheritance](/knowledge/molecular-biology/epigenetic-inheritance)

Epigenetic marks are heritable at two levels: mitotic inheritance (from a cell to its daughter cells) and meiotic inheritance (from an organism to its offspring). Mitotic inheritance is well established. During DNA replication, DNMT1 recognizes hemimethylated CpG sites and methylates the newly synthesized strand, ensuring that methylation patterns are faithfully copied. Histone modifications are also propagated, although the mechanism is less well understood; it likely involves the recognition of existing marks by histone-modifying enzymes that modify new histones as they are deposited.

Meiotic inheritance of epigenetic marks—**transgenerational [epigenetic inheritance](/knowledge/molecular-biology/epigenetic-inheritance)**—is more controversial but has been demonstrated in several organisms. In plants, paramutations and transposable element silencing can be inherited for many generations. In mammals, the *Agouti* gene in mice provides a classic example: the methylation state of an upstream retrotransposon determines coat color, and this state can be passed to offspring. However, most epigenetic marks are erased and re-established during gametogenesis and early embryogenesis. The genome undergoes two waves of demethylation—one in the primordial germ cells and one in the preimplantation embryo—followed by de novo methylation. Only a small number of loci, including imprinted genes and some transposable elements, escape this reprogramming.

Environmental factors can influence epigenetic marks that are then transmitted to offspring. In the Dutch Hunger Winter of 1944–1945, children conceived during the famine had altered methylation at the *IGF2* locus compared to their siblings conceived before or after, and these differences persisted for decades. Whether such changes are truly inherited across multiple generations in humans remains an active area of research.

### Germline vs. Somatic Mutations

Mutations are also heritable, but the rules are different. A mutation in a somatic cell is passed to all daughter cells of that cell but not to offspring. A mutation in a germline cell is passed to the next generation and will be present in every cell of the offspring.

The stability of mutations is much greater than that of epigenetic marks. Once a mutation is fixed in the genome, it is copied with high fidelity during DNA replication. The error rate of DNA polymerase is approximately 10⁻⁹ to 10⁻¹⁰ per base pair per replication, and proofreading and mismatch repair reduce this further. In contrast, epigenetic marks can be lost or gained in response to environmental signals, and the enzymes that maintain them are not infallible. The rate of spontaneous epimutation (loss or gain of a methylation mark) is estimated to be 10⁻³ to 10⁻⁴ per locus per generation—orders of magnitude higher than the rate of genetic mutation.

This difference in stability has important consequences. Mutations provide a permanent record of evolutionary history, which is why they are used for phylogenetic analysis and forensic identification. Epigenetic marks are more plastic, allowing organisms to adapt to environmental changes within a single generation. However, this plasticity also means that epigenetic changes are less reliable as biomarkers across long time scales.

## Methods to Study Epigenetics and Mutations

### Epigenetic Profiling Techniques

Studying epigenetic modifications requires methods that can detect chemical modifications without altering the DNA sequence.

**Bisulfite sequencing** is the gold standard for DNA methylation analysis. Treatment of genomic DNA with sodium bisulfite converts unmethylated cytosines to uracil, while methylated cytosines remain unchanged. After PCR amplification and sequencing, the presence of a cytosine at a CpG site indicates methylation, while a thymine (converted from uracil) indicates the absence of methylation. The standard protocol uses 3 M sodium bisulfite at pH 5.0, incubated at 50°C for 12–16 hours. Whole-genome bisulfite sequencing (WGBS) provides single-nucleotide resolution of methylation across the entire genome, but it is expensive. Reduced representation bisulfite sequencing (RRBS) enriches for CpG-rich regions by digesting DNA with *MspI* (which cuts at CCGG sites) and selecting fragments of 40–220 base pairs.

**Chromatin immunoprecipitation followed by sequencing (ChIP-seq)** identifies the genomic locations of histone modifications or DNA-binding proteins. Cells are treated with formaldehyde to cross-link proteins to DNA, the chromatin is sheared by sonication to fragments of 200–600 base pairs, and an antibody specific to the modification of interest (e.g., anti-H3K4me3) is used to immunoprecipitate the protein-DNA complexes. After reversing the cross-links, the DNA is purified and sequenced. ChIP-seq requires 10⁶–10⁷ cells and typically 10–20 million sequencing reads per sample.

**ATAC-seq** (Assay for Transposase-Accessible Chromatin) maps open chromatin regions. The hyperactive Tn5 transposase simultaneously cuts and inserts sequencing adapters into accessible DNA, while inaccessible regions remain intact. After PCR amplification and sequencing, peaks of read density indicate regions of open chromatin. ATAC-seq requires only 500–50,000 cells, making it suitable for rare cell populations.

### Mutation Detection Methods

Mutations are detected by directly examining the DNA sequence.

**Sanger sequencing** remains the standard for validating known mutations. It uses chain-terminating dideoxynucleotides to generate a ladder of fragments that are separated by capillary electrophoresis. A typical reaction uses 10–50 ng of template DNA, 3.2 pmol of primer, and 0.5 μL of BigDye Terminator mix in a 10 μL reaction, cycled 25–30 times with an annealing temperature of 50–60°C.

**Next-generation sequencing (NGS)** allows high-throughput detection of mutations across large genomic regions. Targeted panels sequence specific genes of interest, whole-exome sequencing captures all protein-coding regions (approximately 1.5% of the genome), and whole-genome sequencing covers all 3.2 billion base pairs. Variant calling algorithms compare the sequenced reads to a reference genome and identify differences.

**PCR-based methods** are used for detecting known mutations. Allele-specific PCR uses primers whose 3' ends match either the wild-type or mutant sequence; amplification occurs only when the primer perfectly matches the template. Quantitative PCR (qPCR) can detect mutations in real time using fluorescent probes. For a comparison of PCR and its quantitative variant, see the [Difference Between PCR and qPCR](/knowledge/molecular-biology/difference-between-pcr-and-qpcr).

**Karyotyping** and **fluorescence [in situ hybridization](/knowledge/molecular-biology/in-situ-hybridization) (FISH)** detect chromosomal abnormalities. Karyotyping involves arresting cells in metaphase, staining chromosomes with Giemsa, and examining the banding pattern under a microscope. FISH uses fluorescently labeled DNA probes that hybridize to specific chromosomal regions, allowing detection of deletions, duplications, and translocations.

The choice of method depends on the question. To determine whether a change in gene expression is due to a mutation or an epigenetic alteration, one would sequence the gene (to detect mutations) and perform bisulfite sequencing or ChIP-seq (to detect epigenetic marks). This combined approach is essential for distinguishing between the two mechanisms.

## Role in Disease and Evolution

### Epigenetics in Cancer

Cancer is a disease of both genetic and epigenetic alterations. The classic model of carcinogenesis emphasizes the accumulation of mutations in oncogenes and [tumor suppressor genes](/knowledge/molecular-biology/tumor-suppressor-gene). However, it is now clear that epigenetic changes are equally important and often occur earlier.

**Tumor suppressor genes** are frequently silenced by promoter hypermethylation in cancer. The *CDKN2A* gene, which encodes the p16^INK4a cell cycle inhibitor, is silenced by methylation in a wide range of tumors, including melanoma, pancreatic cancer, and glioblastoma. The *MLH1* gene, involved in DNA mismatch repair, is silenced by methylation in approximately 15% of sporadic colorectal cancers, leading to microsatellite instability. These epigenetic changes produce the same loss of function as inactivating mutations but are potentially reversible with drugs that inhibit DNMTs.

**Oncogenes** can be activated by mutations or by epigenetic changes. Hypomethylation of oncogene promoters can lead to overexpression. For example, the *HRAS* oncogene is overexpressed in some bladder cancers due to loss of methylation at its promoter. Global hypomethylation, which is common in cancer, also promotes genomic instability by reactivating transposable elements and destabilizing centromeric regions.

The reversibility of epigenetic changes makes them attractive therapeutic targets. The DNMT inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine) are incorporated into DNA during replication, where they covalently trap DNMT1, leading to its degradation and passive demethylation. HDAC inhibitors such as vorinostat and romidepsin increase histone acetylation, reactivating silenced genes. These drugs are approved for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphoma.

The interplay between genetics and epigenetics in cancer is complex. A mutation in a chromatin remodeling gene, such as *ARID1A* (a subunit of the SWI/SNF complex), can cause widespread epigenetic dysregulation. Conversely, epigenetic silencing of a DNA repair gene can increase the mutation rate. For a more detailed discussion of the relationship between these mechanisms, see [Epigenetics vs Mutation](/knowledge/molecular-biology/epigenetics-vs-mutation).

### Mutations and Natural Selection

Mutations are the ultimate source of genetic variation and the raw material for evolution. They arise randomly with respect to fitness, and natural selection acts on the resulting phenotypes. Most mutations are neutral or deleterious, but a small fraction are beneficial and increase in frequency over time.

The rate of mutation is not uniform across the genome. Mutation rates are higher in CpG dinucleotides because methylated cytosines can undergo spontaneous deamination to thymine, creating a C→T transition. This is why CpG sites are hotspots for mutations. The mutation rate is also higher in male germ cells than in female germ cells, because spermatogonia divide more frequently than oogonia, accumulating more replication errors.

Epigenetic variation can also contribute to evolution, although its role is more debated. Epigenetic changes can produce phenotypic variation that is subject to selection, and in some cases, this variation can be inherited. In plants, epigenetic variants (epialleles) can arise at rates 10³–10⁵ times higher than genetic mutations, providing a rapid source of phenotypic diversity. However, because epigenetic marks are less stable than DNA sequences, their long-term evolutionary significance is limited. The [Difference Between Epigenetic and Genetic](/knowledge/molecular-biology/difference-between-epigenetic-and-genetic) article provides further context on how these two types of variation interact.

## Common Pitfalls and Misconceptions

### Reversibility vs. Permanence

A common error is to assume that all epigenetic changes are easily reversible and all mutations are permanent. While it is true that epigenetic marks can be removed by enzymes, some epigenetic states are remarkably stable. The inactive X chromosome in female mammals is maintained as heterochromatin for the entire lifespan of the organism. Imprinted genes maintain their parent-of-origin-specific methylation throughout life. In contrast, some mutations can be reversed, albeit rarely. A second mutation can restore the original sequence (reversion), or a mutation in a different gene can compensate for the first (suppressor mutation).

Another misconception is that epigenetic changes are always "soft" or "minor" compared to mutations. In reality, epigenetic silencing of a tumor suppressor gene can be as devastating as an inactivating mutation. The loss of *MLH1* expression by promoter methylation produces the same phenotype as a truncating mutation in the gene.

### Environmental Influence vs. Randomness

Students often assume that epigenetic changes are always environmentally induced, while mutations are always random. This is incorrect. Many epigenetic changes occur as part of normal development, independent of environmental cues. The random inactivation of one X chromosome in each female cell is a stochastic process, not a response to the environment. Conversely, mutations can be induced by environmental factors. Ultraviolet radiation causes pyrimidine dimers that lead to C→T transitions; tobacco smoke contains chemicals that form DNA adducts; ionizing radiation causes double-strand breaks. The key difference is not the cause but the molecular nature of the change: epigenetic modifications are chemical additions to existing molecules, while mutations alter the sequence of nucleotides.

A related error is to think that epigenetic changes are "softer" or "less real" than mutations. Both are physical changes to the genome that can have profound phenotypic consequences. The distinction is mechanistic, not qualitative.

## Practical Summary: Key Differences at a Glance

The following table summarizes the essential differences between epigenetics and mutation:

| Feature | Epigenetic Modification | Mutation |
|---------|------------------------|----------|
| **Molecular change** | Chemical modification (methyl, acetyl) to DNA or histones | Change in DNA nucleotide sequence |
| **DNA sequence altered?** | No | Yes |
| **Reversibility** | Reversible (enzymes remove or add marks) | Irreversible (except rare reversion) |
| **Stability** | Dynamic; can change in response to signals | Stable; copied faithfully during replication |
| **Heritability** | Mitotic; occasionally meiotic (transgenerational) | Mitotic and meiotic (germline) |
| **Rate of occurrence** | High (10⁻³–10⁻⁴ per locus per generation) | Low (10⁻⁹–10⁻¹⁰ per base pair per replication) |
| **Effects on gene expression** | On/off regulation; graded; reversible | Loss or gain of function; often binary |
| **Detection methods** | Bisulfite sequencing, ChIP-seq, ATAC-seq | DNA sequencing, PCR, karyotyping |
| **Role in disease** | Silencing of tumor suppressors; reactivation of oncogenes | Oncogenic activation; tumor suppressor inactivation |
| **Therapeutic targeting** | DNMT inhibitors, HDAC inhibitors | Targeted therapies (e.g., kinase inhibitors) |

Key points to remember:

- Epigenetics changes gene expression without changing the DNA sequence; mutations change the sequence itself.
- Epigenetic marks are reversible and dynamic; mutations are permanent and stable.
- Both can be inherited, but epigenetic inheritance is less stable and more influenced by the environment.
- Both contribute to cancer and other diseases, often synergistically.
- Epigenetic changes can be targeted by drugs; mutations require different therapeutic strategies.

## Frequently Asked Questions

### What is the main difference between epigenetics and mutation?

The main difference is that a mutation is a permanent change in the DNA nucleotide sequence, while an epigenetic modification is a reversible chemical change that alters gene expression without changing the sequence. Mutations change the genetic information itself; epigenetic changes alter how that information is read.

### Can epigenetic changes be inherited?

Yes, but with important caveats. Epigenetic marks are faithfully inherited during cell division (mitotic inheritance), which is how differentiated cells maintain their identity. Transgenerational inheritance (passing epigenetic marks from parent to offspring) occurs in plants and some animals, but in mammals, most marks are erased and re-established during gametogenesis and embryogenesis. Only a few loci, such as imprinted genes, reliably transmit epigenetic information across generations.

### Are epigenetic changes reversible?

Yes, by definition. Epigenetic marks are added and removed by enzymes. DNA methylation can be removed passively (by failure to maintain marks during replication) or actively (by TET enzymes that oxidize 5-methylcytosine). Histone modifications are removed by HDACs and demethylases. This reversibility is the basis for epigenetic therapies in cancer.

### Do mutations always cause disease?

No. Most mutations are neutral, meaning they have no effect on phenotype. This can occur because the mutation is in a non-coding region, is silent (does not change the amino acid), or changes an amino acid that does not affect protein function. Many mutations are also deleterious but are present in a recessive state, causing no phenotype in heterozygotes. Only a small fraction of mutations are beneficial or pathogenic.

### How can I distinguish between an epigenetic change and a mutation in a lab?

Sequence the DNA to detect mutations and perform epigenetic profiling to detect modifications. If the DNA sequence is identical between two samples but gene expression differs, the difference is likely epigenetic. Bisulfite sequencing will reveal methylation differences, ChIP-seq will reveal histone modification differences, and ATAC-seq will reveal chromatin accessibility differences. If the DNA sequence differs, a mutation is present.

### Which is more important in cancer: epigenetics or mutation?

Both are important and often cooperate. Some cancers are driven primarily by mutations (e.g., chronic myeloid leukemia, driven by the BCR-ABL fusion). Others are driven primarily by epigenetic changes (e.g., some glioblastomas with *MGMT* promoter methylation). In most cancers, both types of alterations accumulate, and the distinction matters for treatment: epigenetic changes can be targeted with DNMT or HDAC inhibitors, while mutations may be targetable with specific inhibitors.

### Can environmental factors cause mutations?

Yes. Ultraviolet radiation causes pyrimidine dimers that lead to C→T transitions in skin cells. Ionizing radiation causes double-strand breaks and chromosomal rearrangements. Chemical mutagens, such as those in tobacco smoke, form DNA adducts that cause base mispairing during replication. However, mutations also arise spontaneously from errors in DNA replication and from the intrinsic instability of certain bases, such as the deamination of methylated cytosines.

## Key Takeaways

- Mutations are permanent changes in DNA sequence; epigenetic modifications are reversible chemical changes that do not alter the sequence.
- Epigenetic regulation operates through DNA methylation, histone modifications, and chromatin remodeling, all of which control gene accessibility.
- Mutations can be point mutations, insertions, deletions, or chromosomal rearrangements, and they cause loss or gain of protein function.
- Epigenetic marks are heritable during cell division and occasionally across generations, but they are far less stable than mutations.
- Both mechanisms contribute to cancer: epigenetic silencing of tumor suppressors and mutations in oncogenes are common and often co-occur.
- Epigenetic changes are detected by bisulfite sequencing, ChIP-seq, and ATAC-seq; mutations are detected by DNA sequencing, PCR, and karyotyping.
- The reversibility of epigenetic changes makes them druggable targets, whereas mutations require different therapeutic approaches.


<div data-calculator="molecular-cloning"></div>

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)